



The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factors

Holger Hengel^{1,2} · Peter Martus³ · Jennifer Faber^{4,5} · Paola Giunit^{8,9} · Hector Garcia-Moreno^{8,9} · Nita Solanky^{8,9} · Thomas Klockgether^{4,5} · Kathrin Reetz^{10,11} · Bart P. van de Warrenburg¹² · Magda M. Santana^{13,14} · Patrick Silva^{13,14,15} · Inês Cunha^{13,14} · Luís Pereira de Almeida^{13,14,15} · Dagmar Timmann¹⁶ · Jon Infante^{17,18} · Jeroen de Vries¹⁹ · Manuela Lima²⁰ · Paula Pires²⁰ · Khalaf Bushara²¹ · Heike Jacobi²² · Chiadi Onyike²³ · Jeremy D. Schmahmann²⁴ · Jeannette Hübener-Schmid^{6,7} · Matthias Synofzik^{1,2} · European Spinocerebellar Ataxia Type-3/Machado-Joseph Disease Initiative (ESMI) Study Group · Ludger Schöls^{1,2}

Received: 6 September 2022 / Revised: 17 October 2022 / Accepted: 19 October 2022
© The Author(s) 2022

Abstract

Background Non-motor symptoms (NMS) are a substantial burden for patients with SCA3. There are limited data on their frequency, and their relation with disease severity and activities of daily living is not clear. In addition, lifestyle may either influence or be affected by the occurrence of NMS.

Objective To characterize NMS in SCA3 and investigate possible associations with disease severity and lifestyle factors.

Methods In a prospective cohort study, we performed a cross-sectional analysis of NMS in 227 SCA3 patients, 42 pre-ataxic mutation carriers, and 112 controls and tested for associations with SARA score, activities of daily living, and the lifestyle factors alcohol consumption, smoking and physical activity.

Results Sleep disturbance, restless legs syndrome, mild cognitive impairment, depression, bladder dysfunction and paresthesia were frequent among SCA3 patients, while mainly absent in pre-ataxic mutation carriers. Except for restless legs syndrome, NMS correlated significantly with disease severity and activities of daily living. Alcohol abstinence was associated with bladder dysfunction. Patients with higher physical activity showed less cognitive impairment and fewer depressive symptoms, but these differences were not significant.

Conclusion This study revealed a clear association between disease severity and NMS, likely driven by the progression of the widespread neurodegenerative process. Associations between lifestyle and NMS can probably be attributed to the influence of NMS on lifestyle.

Keywords SCA3 · Non-motor symptoms · Lifestyle · Physical activity

Introduction

Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly inherited spinocerebellar ataxia. Clinical symptoms in SCA3 are not restricted to progressive cerebellar ataxia, but extra-cerebellar motor symptoms and non-motor symptoms (NMS) contribute to disease burden [27], and NMS may even constitute the first manifestation of the disease [8]. Frequently observed NMS in SCA3 are sleep disturbance, fatigue, restless legs syndrome (RLS), neuropathy,

mild cognitive decline, depression, and bladder disturbance [7, 13, 16, 19, 21, 22, 26–28, 33]. Data on the frequencies of NMS among large SCA3 cohorts are scarce, and the correlation of NMS with disease severity is only shown in parts [32]. In addition, some of these NMS are likely to influence the functional status and the lifestyle of the patients. Vice versa, different lifestyle factors might influence the severity of NMS. Detailed knowledge and awareness of NMS in SCA3 might help to enhance symptomatic treatment for these symptoms.

In this multicentric observational study, we investigated the prevalence of NMS in 227 SCA3 patients compared to 112 healthy controls as well as in 42 pre-ataxic mutation carriers. Furthermore, we assessed the association of NMS

✉ Ludger Schöls
ludger.schoels@uni-tuebingen.de

Extended author information available on the last page of the article

with disease severity (SARA), functional status (activities of daily living), and their association with lifestyle factors.

Methods

Study cohort and data collection

Based on the European Spinocerebellar ataxia type 3/Machado-Joseph disease initiative (ESMI) cohort study, a cross-sectional analysis was performed on datasets from 227 ataxic SCA3 mutation carriers, 42 pre-ataxic carriers, and 112 age- and sex-matched healthy controls from eleven European and four associated US sites. As described earlier, ataxia severity was quantified using the Scale for the Assessment and Rating of Ataxia (SARA) [8, 29]. Functional status was evaluated by the self-reported Activities of Daily Living score (ADL) of the Friedreich's Ataxia Rating Scale (FARS) [23]. NMS were collected using the PSQI questionnaire for Sleep Quality [5], the MoCA test for cognitive deficits [20], and the PHQ-9 questionnaire for depressive symptoms [15]. The presence of RLS was evaluated according to the updated International RLS Study Group consensus criteria [2]. Urinary dysfunction and paresthesia were assessed with the Inventory of Non-Ataxia Signs (INAS) [12].

Lifestyle data were collected as previously described [9]. Specifically, physical activity was evaluated using the short form of the International Physical Activity Questionnaire (IPAQ), and data were processed according to standard recommendations [6]. Wheelchair-bound patients were excluded from further analysis regarding physical activity, as the walking domain was not applicable. Based on the IPAQ, multiples of the resting metabolic rate (MET) minutes/week were estimated, and probands were categorized into three levels of physical activity (high, moderate and low) following the IPAQ guidelines. A moderate level of physical activity on the IPAQ approximately reflects the minimum recommendation of physical activity of the WHO [4]. Alcohol consumption was assessed in a standardized interview asking about consumption on the previous workday and over the last weekend, allowing for a rough estimation of daily alcohol consumption [11]. The study was approved by the local institutional review boards of all participating centers. Written informed consent was obtained from all study participants before enrollment.

Statistics

Data were analyzed using RStudio Version 1.2.5033. As none of the outcome parameters were normally distributed, the nonparametric Kruskal–Wallis test followed by the Mann–Whitney *U* test was used for group comparisons. Correlations were calculated using Spearman's rank correlation.

Bonferroni correction was applied as follows: comparison of NMS in SCA3 probands, pre-ataxic mutation carriers and controls with $m = 6$ for 6 different NMS. Accordingly, $p < 0.00833$ was considered significant for the prevalence of NMS shown in Table 1. Correlations with SARA, smoking, alcohol consumption and physical activity were only tested if NMS were significantly more frequent in the SCA3 group compared to the control group. Again $p < 0.00833$ was used as significance level in these follow-up tests (Figs. 1, 2, 3, 4). All other analyses were considered exploratory and tested for $p < 0.00833$.

Results

Characteristics of the study population are listed in Table 1. The NMS impaired sleep quality (PSQI), cognitive deficits (MoCA), depression (PHQ-9), bladder dysfunction, restless legs syndrome (RLS) and paresthesia were all highly significant more frequent in SCA3 patients compared to controls (Table 1).

In detail, poor sleep quality (PSQI > 5) was detected in 54% of SCA3 patients compared to 36% of controls and 30% in pre-ataxic mutation carriers. Mild cognitive impairment (MoCA 18–25 points) was found in 31% of SCA3 patients compared to 15% of control patients and 23% of pre-ataxic mutation carriers. Moderately reduced MoCA scores (10–17 points) were found in 5% of SCA3 and in none of the control probands or pre-ataxic mutation carriers. Two SCA3 probands and none of the control or pre-ataxic probands had severely reduced MoCA scores (< 10 points). PHQ-9 scores were higher in SCA3 probands compared to controls, indicating more depressive symptoms (median 7 points in SCA3 compared to 3 points in controls and 5 points in pre-ataxic probands). RLS was present in 17% of SCA3 probands, only 1% of healthy controls, and none of the pre-ataxic mutation carriers. Bladder dysfunction (mild, moderate, or severe) was present in 56% of SCA3 probands, while only 9% of healthy controls and 6% of pre-ataxic mutation carriers reported bladder problems. Paresthesia at the ankles (< 5/8) was present in 47% of SCA3 probands, 8% of controls, and none of the pre-ataxic participants.

While none of the NMS were significantly different between pre-ataxic mutation carriers and controls, there were noticeable more depressive symptoms in pre-ataxic mutation carriers compared to controls ($p = 0.012$, not significant with Bonferroni adjusted significance level 0.00833).

Based on the hypothesis that the neurodegenerative process leads to a progression of both motor and non-motor symptoms, we tested correlations of these NMS with the severity of ataxia measured by the SARA score. Correlation analysis of PSQI, MoCA and PHQ-9 with the SARA score indicated that sleep quality, cognitive deficits, and

Table 1 Characteristics of the study population and occurrence of non-motor symptoms

Demographic information	Ataxic SCA3	Pre-ataxic SCA3	Controls	<i>p</i> value pre-ataxic vs. controls	<i>p</i> value ataxic SCA3 vs. controls
Probands (<i>n</i>)	227	42	112		
Sex (f; m)	124 (51%); 119	25 (59%); 17	60 (50%); 59		
Age	51 (41.5–60.0)	34.0 (29.0–40.0)	46.5 (38.0–59.25)		
Age of onset (years)	39.0 (33.0–47.0)	NA	NA		
CAG repeat length (longer allele)	70.0 (67.0–73.0)	68 (62.0–70)	NA		
SARA	12 (8.0–19.0)	1 (0–2.0)	0 (0–0.5)		
ADL	9.0 (5.0–16.0)	0 (0–1.0)	0 (0–0)		
Alcohol (yes; previously; no)	127 (57%); 60 (27%); 35 (16%)	35 (83%); 4 (10%); 3 (7%)	96 (87%); 6 (5%); 9 (8%)		
Physical activity (high; mod; low)	51 (29%); 54 (31%); 71 (40%)	22 (56%); 8 (21%); 9 (23%)	37 (43%); 33 (39%); 15 (18%)		
Smoking (yes; previously; no)	9 (5%); 44 (24%); 130 (71%)	15 (36%); 5 (12%); 22 (52%)	9 (8%); 44 (37%); 64 (55%)		
PSQI [points]	6 (4–10)	4 (4–6.25)	4 (3–7)	0.72	$*3.8 \times 10^{-5}$
MoCA [points]	27 (24–28)	27 (26–29)	28 (27–29)	0.14	$*7.2 \times 10^{-7}$
PHQ9 [points]	7 (4–12)	5 (2–9)	3 (1–4)	0.012	$*2.5 \times 10^{-15}$
Restless legs syndrome	17%	0%	1%	1.0	$*1.6 \times 10^{-5}$
Bladder dysfunction (mild; mod; sev)	26%; 23%; 6%	3%; 3%; 0%	7%; 0%; 2%	0.65	$*3.1 \times 10^{-13}$
Pallhypesthesia (< 5/8; < 2/8)	31%; 16%	0%; 0%	6%; 2%	0.07	$*1.0 \times 10^{-10}$

* represent significant values

Data are presented as *n* (%) or median (interquartile range). *p* values were calculated using the Kruskal–Wallis test, followed by the Mann–Whitney *U* test. After Bonferroni correction for multiple testing (number of tested NMS (*m*) = 6), results were considered to be significant at $P < 0.00833$. Overall comparisons using the Kruskal–Wallis tests was significant for all NMS, and followed by pairwise comparison using Mann–Whitney *U* test (*p* values listed in column 5 and 6)

SCA3 spinocerebellar ataxia type 3; MoCA Montreal-Cognitive-Assessment; PHQ9 9-question Patient Health Questionnaire; SARA Scale for the Assessment and Rating of Ataxia; ADL Activities of Daily Living; NA not available; mod moderate; sev severe

depression worsened with increasing motor disease severity (Fig. 1 A–C). Likewise, bladder dysfunction and pallhypesthesia were significantly associated with higher SARA scores (Fig. 1E, F). The presence of RLS was not associated with higher SARA scores (Fig. 1D).

Similar correlations and associations were found for the activities of daily living score (ADL). Higher (i.e., worse) ADL scores were associated with sleep disturbance, cognitive impairment, depression and pallhypesthesia (Supplementary Fig. 1). As bladder dysfunction is a part of the ADL score, no correlation analysis was calculated between bladder dysfunction and the ADL score.

Explorative analyses of the influence of age and repeat length on NMS showed a clear association between higher age and pallhypesthesia (Supplementary Fig. 2F) and an association between a shorter repeat length and pallhypesthesia. When probands were stratified for age > 45 years, there was no association between pallhypesthesia and repeat length ($p = 0.89$, data not shown), suggesting that

the correlation between repeat length and pallhypesthesia was due to age differences. Furthermore, higher PHQ-9 scores were correlated with longer repeats (Supplementary Fig. 3C).

Finally, we explored potential associations between non-motor symptoms and the lifestyle factors physical activity (Fig. 2), alcohol consumption (Fig. 3) and smoking (Fig. 4). We found better cognition and less depression in patients with higher activity levels. However, these differences were not statistically significant with the Bonferroni adjusted significance level of 0.00833 (Fig. 2B, C, $p = 0.015$ and $p = 0.039$, respectively). Urinary dysfunction and sleep quality (PSQI) were only slightly better in patients with high activity levels (Fig. 2A, E). Pallhypesthesia and RLS were independent from physical activity levels (Fig. 2D, F).

Alcohol consumption was highly significantly associated with less bladder dysfunction (Fig. 3E, $p = 1.1 \times 10^{-4}$). MoCA scores were slightly higher in patients consuming alcohol compared to patients who

Fig. 1 Associations between NMS and SARA scores. **PSQI** and **PHQ-9** were positively correlated with **SARA** (**A**, **C**). **MoCA** was negatively correlated with **SARA**. **RLS** was independent from **SARA**. **E** **Bladder dysfunction** and (**F**) **pallhypesthesia** were highly significantly associated with **SARA** scores. $p < 0.00833$ was considered significant





Fig. 2 Associations between physical activity and NMS. **A** **PSQI** was not related to physical activity levels. **B** **MoCA** scores were better in subjects with higher physical activity, not significant after Bonferroni correction. **C** **PHQ-9** scores were to lower in subjects with higher physical activity, not significant after Bonferroni correction. **D** Physical activity had no influence on **RLS** and (**E**) only minor associations with urinary dysfunction. **F** **Pallhypesthesia** was independent of physical activity levels. $p < 0.00833$ was considered significant



never had drunk or stopped drinking alcohol (Fig. 3B, $p = 0.044$). PSQI scores, PHQ-9 scores, pallhypesthesia and RLS were not associated with alcohol consumption (Fig. 3A, C, D, F).

Smokers had more depressive symptoms than non-smokers, but the difference was not statistically significant

after Bonferroni correction (Fig. 4C, $p = 0.028$). Other NMS were not associated with smoking.

Fig. 3 Associations between alcohol consumption and NMS. **A** PSQI, **B** MoCA, **C** PHQ-9, **D** RLS, and **F** pallesthesia were not associated with alcohol consumption, abstinence, or previous alcohol consumption. **E** Urinary dysfunction was significantly associated with alcohol abstinence. $p < 0.00833$ was considered significant





Fig. 4 Associations between smoking and NMS. **A** PSQI, **B** MoCA, **D** RLS, **E** urinary dysfunction, **F** pallesthesia. PHQ-9 showed more depressive symptoms in smokers, not significant after Bonferroni correction **C**. $p < 0.00833$ was considered significant



Discussion

In this observational study, NMS including sleep disturbance, cognitive deficits, depression, RLS, bladder dysfunction and pallesthesia were significantly more common in SCA3 patients than in control subjects. Their frequency and severity increased in parallel with the SARA score. In pre-ataxic mutation carriers, NMS were not significantly more frequent than in healthy controls.

Autopsy studies confirmed widespread neurodegeneration in SCA3 [24, 25], in multiple CNS regions outside the cerebellum and in the peripheral nervous system, and is the likely cause of the parallel increase of NMS with disease severity assessed by the SARA score. These findings are in line with a recent study that found fatigue to increase with the severity of ataxia in SCA3 [32]. The authors suggested a bidirectional relationship between ataxia and fatigue as an explanation, but parallel worsening of both symptoms due to the parallel spread of neurodegeneration affecting multiple regions in the brain might also be a suitable explanation

here. On the other hand, sensory deficits and sleep disturbances could lead to poorer performance of the SARA score. As an exception, RLS was not associated with the SARA score.

In its first description in SCA3, RLS was found to be associated with signs of peripheral neuropathy and extrapyramidal signs but not with age or repeat length [14]. This is in line with the findings from our study, where RLS did not correlate with age, the number of CAG repeats, or lifestyle factors. The strong correlation of non-motor symptoms with ADL scores could indicate that NMS lead to limitations in activities of daily living. However, the ADL score was shown to be highly correlated with the SARA score, both measuring disease progression. Thus, an association with non-motor symptoms that worsen as the disease progresses seems at hand. Interestingly, higher age was only associated with paresthesia in SCA3 patients, while longer CAG repeats were associated with more depressive symptoms but better-preserved vibration sense. Peripheral neuropathy and sensory deficits have been reported earlier to be frequent in patients with shorter repeat expansions and almost not present in repeat lengths above 72 (CAG)[30]. Indeed, in our data, patients with paresthesia < 2/8 all had a CAG repeat length below 73 (CAG) (Supplementary Fig. 3F). The most likely explanation is that patients with longer repeats do not reach the higher age at which neuropathy often first manifests. By stratifying for probands older than 45 years, no association between repeat length and paresthesia is present; thus, strengthening the hypothesis that age but not repeat length is the critical factor here.

Regarding the observed associations between lifestyle factors and non-motor symptoms, it is not possible to establish causal relationships due to the observational nature of this study. The observed better MoCA scores and lower depression scores in patients with higher physical activity levels were not statistically significant at a Bonferroni adjusted significance level of 0.00833. This is likely due to underpowering of the study with a conservative design and conservative correction for multiple testing. Comparing only the high vs. low activity groups in an exploratory approach results in $p = 0.0047$ for MoCA and $p = 0.019$ for PHQ9. These differences may reflect, in part, a protective effect of physical activity for cognitive decline and depression. A risk reduction of cognitive decline, dementia and/or Alzheimer's disease due to physical activity has been suggested multiple times [1, 17, 18]. Similarly, a protective or even therapeutic effect of physical activity on depression is well established [10, 31]. However, it is also possible that less depression and better cognition lead to more physical activity due to better drive and motivation.

Associations of alcohol consumption and NMS was limited to urinary dysfunction. A potential explanation might

be the diuretic effect of alcohol. This may cause increased discomfort from diuresis due to the inhibition of vasopressin production and may lead SCA3 patients with bladder control problems to refrain from alcohol consumption.

Smoking was not significantly associated with any of the NMS. For the general population, an association between smoking and depression is well known [3]. In our study, PHQ-9 scores of SCA3 patients were indeed higher in smokers, yet the differences did not reach significance after Bonferroni correction.

In summary, our study demonstrates NMS to be frequent in SCA3 and to increase with disease severity. As most of them can be ameliorated by symptomatic treatment, awareness and explicit interrogation is important and may help to improve the care of patients with SCA3.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00415-022-11441-z>.

Acknowledgements We are grateful to the patients and their relatives as well as healthy volunteers from the hospital staff for participating in this study.

Funding Open Access funding enabled and organized by Projekt DEAL. This publication is an outcome of ESMI, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). The project was supported through the following funding organizations under the aegis of JPND: Germany, Federal Ministry of Education and Research (BMBF; funding codes 01ED1602A/B); Netherlands, The Netherlands Organisation for Health Research and Development; Portugal, Foundation for Science and Technology (FCT); United Kingdom, Medical Research Council. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 643417. H.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, HE 8803/1–1). At the US sites, this work was in part supported by the National Ataxia Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) grant R01 NS080816. Several authors are members of the European Reference Network for Rare Neurological Diseases—Project No 739510. Bart van de Warrenburg receives research support from ZonMw, Hersenstichting, Gossweiler Foundation, and Radboud university medical center, receives royalties from BSL – Springer Nature, and has served on scientific advisory boards of uniQure and Servier. Jeremy D. Schmahmann is inventor of the CCAS/Schmahmann Scale, the PROM-Ataxia, Brief Ataxia Rating Scale, and Cerebellar Neuropsychiatric Rating Scale to which the General Hospital Corporation holds the copyright. He consults for Biogen and Medavante, receives support from Biohaven and the National Ataxia Foundation, is site PI for Biohaven NCT03952806 and NCT03701399, and receives royalties from Elsevier, MacKeith, Oxford, and Springer. Matthis Synofzik has received consultancy honoraria from Janssen Pharmaceuticals, Ionis Pharmaceuticals, Orphazyme Pharmaceuticals and AviadoBio, all unrelated to the present manuscript.

Declarations

Conflict of interest All authors declare that they have no competing interests to declare that are relevant to the content of this article.

Ethical standards The study was approved by the local institutional review boards of all participating centers. Written informed consent was obtained from all study participants before enrollment.


Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Marques-Aleixo I et al (2021) Preventive and therapeutic potential of physical exercise in neurodegenerative diseases. *Antioxid Redox Signal* 34:674–693
- Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB (2014) Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. *Sleep Med* 15:860–873
- Audrain-McGovern J, Leventhal AM, Strong DR (2015) The role of depression in the uptake and maintenance of cigarette smoking. *Int Rev Neurobiol* 124:209–243
- Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, Carty C, Chaput J-P, Chastin S, Chou R, Dempsey PC, DiPietro L, Ekelund U, Firth J, Friedenreich CM, Garcia L, Gichu M, Jago R, Katzmarzyk PT, Lambert E, Leitzmann M, Milton K, Ortega FB, Ranasinghe C, Stamatakis E, Tiedemann A, Troiano RP, van der Ploeg HP, Wari V, Willumsen JF (2020) World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med* 54:1451
- Buyse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 28:193–213
- Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 35:1381–1395
- D'Abreu A, França M Jr, Conz L, Friedman JH, Nucci AM, Cendes F, Lopes-Cendes I (2009) Sleep symptoms and their clinical correlates in Machado-Joseph disease. *Acta Neurol Scand* 119:277–280
- Globas C, du Montcel ST, Baliko L, Boesch S, Depondt C, DiDonato S, Durr A, Filla A, Klockgether T, Mariotti C, Melegh B, Rakowicz M, Ribai P, Rola R, Schmitz-Hubsch T, Szymanski S, Timmann D, Van de Warrenburg BP, Bauer P, Schols L (2008) Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. *Mov Disorders* 23:2232–2238
- Hengel H, Martus P, Faber J, Garcia-Moreno H, Solanky N, Giunti P, Klockgether T, Reetz K, van de Warrenburg BP, Pereira de Almeida L, Santana MM, Januario C, Silva P, Thieme A, Infante J, de Vries J, Lima M, Ferreira AF, Bushara K, Jacobi H, Onyike C, Schmahmann JD, Hubener-Schmid J, Synofzik M, Schols L (2022) Characterization of lifestyle in spinocerebellar ataxia type 3 and Association with Disease Severity. *Mov Disorders* 37:405–410
- Hu MX, Turner D, Generaal E, Bos D, Ikram MK, Ikram MA, Cuijpers P, Penninx BWJH (2020) Exercise interventions for the prevention of depression: a systematic review of meta-analyses. *BMC Public Health* 20:1255
- Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, Lowe GD, Koenig W (2004) Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). *Eur Heart J* 25:2092–2100
- Jacobi H, Rakowicz M, Rola R, Fancellu R, Mariotti C, Charles P, Dürr A, Küper M, Timmann D, Linnemann C, Schöls L, Kaut O, Schaub C, Filla A, Baliko L, Melegh B, Kang JS, Giunti P, van de Warrenburg BP, Fimmers R, Klockgether T (2013) Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument. *Cerebellum* 12:418–428
- Jang M, Kim HJ, Kim A, Jeon B (2020) Urinary symptoms and urodynamic findings in patients with spinocerebellar Ataxia. *Cerebellum* 19:483–486
- Konieczny M, Bauer P, Tomiuk J, Weisser G, Haan J, Berger K, Riess O, Schöls L (2006) CAG repeats in restless legs syndrome. *Am J Med Genet B* 141:173–176
- Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 16:606–613
- Linnemann C, Tezenas du Montcel S, Rakowicz M, Schmitz-Hubsch T, Szymanski S, Berciano J, van de Warrenburg BP, Pedersen K, Depondt C, Rola R, Klockgether T, García A, Mutlu G, Schöls L (2016) Peripheral neuropathy in spinocerebellar Ataxia type 1, 2, 3, and 6. *Cerebellum* 15:165–173
- Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* 396:413–446
- Marques-Aleixo I, Belez J, Sampaio A, Stevanović J, Coxito P, Gonçalves I, Ascensão A, Magalhães J (2021) Preventive and therapeutic potential of physical exercise in neurodegenerative diseases. *Antioxid Redox Signal* 34:674–693
- Musegante AF, Almeida PN, Barboza AL, Barroso U Jr (2011) Urinary symptoms and urodynamic findings in patients with Machado-Joseph disease. *J Neurol* 258:623–626
- Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 53:695–699
- Pedroso JL, Braga-Neto P, Felício AC, Aquino CC, Prado LB, Prado GF, Barsottini OG (2011) Sleep disorders in cerebellar ataxias. *Arq Neuropsiquiatr* 69:253–257
- Pedroso JL, França MC Jr, Braga-Neto P, D'Abreu A, Saraiva-Pereira ML, Saute JA, Teive HA, Caramelli P, Jardim LB, Lopes-Cendes I, Barsottini OG (2013) Nonmotor and extracerebellar features in Machado-Joseph disease: a review. *Mov Disorders* 28:1200–1208
- Reetz K, Dogan I, Hilgers R-D, Giunti P, Mariotti C, Dürr A, Boesch S, Klopstock T, de Rivera FJR, Schöls L, Klockgether T, Bürk K, Rai M, Pandolfo M, Schulz JB, Nachbauer W, Eigentler A, Depondt C, Benaich S, Charles P, Ewencyk C, Monin M-L, Dafotakis M, Fedosov K, Didszun C, Ermis U, Giordano IA, Timmann D, Karin I, Neuhofer C, Stendel C, Müller vom Hagen J, Wolf J, Panzeri M, Nanetti L, Castaldo A, Arpa J, Sanz-Gallego I, Parkinson MH, Sweeney MG (2016) Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. *Lancet Neurol* 15:1346–1354
- Rüb U, Brunt ER, Deller T (2008) New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). *Curr Opin Neurol* 21:111–116

25. Rüb U, Schöls L, Paulson H, Auburger G, Kermer P, Jen JC, Seidel K, Korf HW, Deller T (2013) Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. *Prog Neurobiol* 104:38–66
26. Schmahmann JD, Caplan D (2006) Cognition, emotion and the cerebellum. *Brain* 129:290–292
27. Schmitz-Hübsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, Filla A, Mariotti C, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BP, Dürr A, Timmann D, Boesch S, Fancellu R, Rola R, Depondt C, Schöls L, Zdienicka E, Kang JS, Döhlinger S, Kremer B, Stephenson DA, Melegh B, Pandolfo M, di Donato S, du Montcel ST, Klockgether T (2008) Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. *Neurology* 71:982–989
28. Schmitz-Hübsch T, Coudert M, Tezenas du Montcel S, Giunti P, Labrum R, Dürr A, Ribai P, Charles P, Linnemann C, Schöls L, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, Mariotti C, Baliko L, Melegh B, Filla A, Salvatore E, van de Warrenburg BP, Szymanski S, Infante J, Timmann D, Boesch S, Depondt C, Kang JS, Schulz JB, Klopstock T, Lossnitzer N, Löwe B, Frick C, Rottländer D, Schlaepfer TE, Klockgether T (2011) Depression comorbidity in spinocerebellar ataxia. *Mov Disorders* 26:870–876
29. Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schöls L, Szymanski S, van de Warrenburg BP, Dürr A, Klockgether T, Fancellu R (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. *Neurology* 66:1717–1720
30. Schöls L, Amoiridis G, Epplen JT, Langkafel M, Przuntek H, Riess O (1996) Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation. *J Neurol Neurosurg Psychiatry* 61:466–470
31. Schuch FB, Vancampfort D, Firth J, Rosenbaum S, Ward PB, Silva ES, Hallgren M, Ponce De Leon A, Dunn AL, Deslandes AC, Fleck MP, Carvalho AF, Stubbs B (2018) Physical activity and incident depression: a meta-analysis of prospective cohort studies. *Am J Psychiatry* 175:631–648
32. Yang JS, Xu HL, Chen PP, Sikandar A, Qian MZ, Lin HX, Lin MT, Chen WJ, Wang N, Wu H, Gan SR (2020) Ataxic severity is positively correlated with fatigue in spinocerebellar Ataxia type 3 patients. *Front Neurol* 11:266
33. Zawacki TM, Grace J, Friedman JH, Sudarsky L (2002) Executive and emotional dysfunction in Machado-Joseph disease. *Mov Disorders* 17:1004–1010

Authors and Affiliations

Holger Hengel^{1,2} · Peter Martus³ · Jennifer Faber^{4,5} · Paola Giunti^{8,9} · Hector Garcia-Moreno^{8,9} · Nita Solanky^{8,9} · Thomas Klockgether^{4,5} · Kathrin Reetz^{10,11} · Bart P. van de Warrenburg¹² · Magda M. Santana^{13,14} · Patrick Silva^{13,14,15} · Inês Cunha^{13,14} · Luís Pereira de Almeida^{13,14,15} · Dagmar Timmann¹⁶ · Jon Infante^{17,18} · Jeroen de Vries¹⁹ · Manuela Lima²⁰ · Paula Pires²⁰ · Khalaf Bushara²¹ · Heike Jacobi²² · Chiadi Onyike²³ · Jeremy D. Schmahmann²⁴ · Jeannette Hübener-Schmid^{6,7} · Matthis Synofzik^{1,2} · European Spinocerebellar Ataxia Type-3/Machado-Joseph Disease Initiative (ESMI) Study Group · Ludger Schöls^{1,2} 

¹ Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany

² German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany

³ Institute of Clinical Epidemiology and Applied Biostatistics, University of Tübingen, Tübingen, Germany

⁴ German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

⁵ Department of Neurology, University Hospital Bonn, Bonn, Germany

⁶ Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

⁷ Centre for Rare Diseases, University of Tuebingen, Tübingen, Germany

⁸ Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK

⁹ Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK

¹⁰ Department of Neurology, RWTH Aachen University, Aachen, Germany

¹¹ JARA-Brain Institute Molecular Neuroscience and Neuroimaging, Forschungszentrum Jülich, Jülich, Germany

¹² Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands

¹³ Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal

¹⁴ Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal

¹⁵ Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

¹⁶ Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Essen University Hospital, University of Duisburg-Essen, Essen, Germany

¹⁷ Neurology Service, University Hospital Marqués de Valdecilla-IDIVAL, University of Cantabria (UC), Santander, Spain

¹⁸ Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

¹⁹ Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

- ²⁰ Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal
- ²¹ Department of Neurology, University of Minnesota, Minneapolis, MN, USA
- ²² Department of Neurology, University Hospital of Heidelberg, Heidelberg, Germany

- ²³ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ²⁴ Ataxia Center, Cognitive Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA